2145091-51-4

Pacmilimab induces antitumor responses comparable to those of the same dose of the parental antibody in mice bearing MC38 tumors^[1].
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity^[1].